Analyst Ratings For NASDAQ:CLVS – Clovis Oncology (NASDAQ:CLVS)
Today, Royal Bank of Canada reiterated its Buy rating on NASDAQ:CLVS – Clovis Oncology (NASDAQ:CLVS) with a price target of $73.00.
Some recent analyst ratings include
- 6/12/2018-Royal Bank of Canada Reiterated Rating of Buy.
- 6/11/2018-Cann Reiterated Rating of Hold.
Recent Insider Trading Activity For NASDAQ:CLVS – Clovis Oncology (NASDAQ:CLVS)
NASDAQ:CLVS – Clovis Oncology (NASDAQ:CLVS) has insider ownership of 10.20% and institutional ownership of 94.01%.
- On 4/9/2018 Thorlef Spickschen, Director, sold 4,500 with an average share price of $60.02 per share and the total transaction amounting to $270,090.00.
- On 3/8/2018 Thorlef Spickschen, Director, sold 4,500 with an average share price of $61.47 per share and the total transaction amounting to $276,615.00.
- On 2/22/2018 Thorlef Spickschen, Director, sold 4,500 with an average share price of $60.00 per share and the total transaction amounting to $270,000.00.
- On 2/15/2018 Gillian C Ivers-Read, Insider, sold 3,000 with an average share price of $54.09 per share and the total transaction amounting to $162,270.00.
- On 1/16/2018 Gillian C Ivers-Read, Insider, sold 3,000 with an average share price of $59.16 per share and the total transaction amounting to $177,480.00.
- On 1/8/2018 Thorlef Spickschen, Director, sold 4,500 with an average share price of $64.97 per share and the total transaction amounting to $292,365.00.
- On 12/15/2017 Gillian C Ivers-Read, Insider, sold 3,000 with an average share price of $64.16 per share and the total transaction amounting to $192,480.00.
Recent Trading Activity for NASDAQ:CLVS – Clovis Oncology (NASDAQ:CLVS)
Shares of NASDAQ:CLVS – Clovis Oncology closed the previous trading session at 43.14 up +0.37 0.87% with 43.44900131225586 shares trading hands.